XOMA reports Q3 net loss of $5.5M, highlights NDA filings and $5M milestone from Day One

XOMA Royalty Corp

2023-Q3 EPS reported -$2.17 revenue$2,925,000

Q3 revenues $0.8M vs $0.5M YoY; net loss $5.5M vs $4.2M YoY.
G&A expenses $6.4M including $2.7M non-cash stock comp; net cash used in ops $2.1M.
Received $6.6M in royalty & milestone payments; ended Q3 with $33.5M cash.
Subsequent: earned $5M milestone from Day One on FDA acceptance of tovorafenib NDA; PDUFA April 30, 2024.
Organon terminated license for ebopiprant; XOMA to seek out-licensing.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

XOMA Royalty Corp reported financial results for the third quarter of 2023.

Period: the third quarter of 2023
Result: reported results

Exact text from the filing

On November 7, 2023, XOMA Corporation issued a press release announcing its financial results for the quarter ended September 30, 2023. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

XOMA Royalty Corp filing history →

Source: SEC EDGAR

accession 0001193125-23-271925

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.